(12) Patent Application Publication (10) Pub. No.: US 2016/0081976 A1 Bromley (43) Pub

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2016/0081976 A1 Bromley (43) Pub US 20160O81976A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0081976 A1 Bromley (43) Pub. Date: Mar. 24, 2016 (54) FORMULATIONS OF WATER-SOLUBLE A6II 45/06 (2006.01) DERVATIVES OF VITAMIN E AND SOFT A63L/22 (2006.01) GEL COMPOSITIONS, CONCENTRATES A61E36/324 (2006.01) AND POWDERS CONTAINING SAME A61E36/85 (2006.01) (71) Applicant: VIRUN, INC., Walnut, CA (US) A647/48 (2006.01) O O A613 L/437 (2006.01) (72) Inventor: Philip J. Bromley, Fullerton, CA (US) (52) U.S. Cl. (21) Appl. No.: 14/866,808 CPC ......... A61 K3I/355 (2013.01); A61K47/48215 (2013.01); A61 K3I/09 (2013.01); A61 K (22) Filed: Sep. 25, 2015 31/202 (2013.01); A61K 31/437 (2013.01); Related U.S. Application Data A6 IK3I/122 (2013.01); A61K 36/324 (2013.01); A61K 36/185 (2013.01); A61 K (63) Continuation of application No. PCT/US2015/ 45/06 (2013.01) 051097, filed on Sep. 18, 2015, Continuation of appli cation No. PCT/US2015/051083, filed on Sep. 18, 2015. (57) ABSTRACT (60) Provisional application No. 62/052,433, filed on Sep. RA's prcity, application N. R Provided herein are compositions that contain water-soluble ed. On Sep. 1S, prov1s1onal application No. itamin E derivati ixtu iti has toco 62/052,435, filed on Sep. 18, 2014, provisional appli- N 1 N. 1Ve t t E. aS f cation No. 62/052,450, filed on Sep. 18, 2014. pheryl polyethylene glycol Succinate ( ), analogS, TPGS homologs and TPGS derivatives. The water-soluble Publication Classification Vitamin E mixtures contain mixtures of dimers and mono (51) Int. Cl mers of the vitamin E derivative. Provided are products con A. 6iK I/355 (2006.01) taining the water-soluble vitamin E derivative mixtures, A6 IK3I/09 (2006.01) including capsules, soft gel compositions, pre-gel composi A6 IK3I/202 (2006.01) tions, emulsions and powders. US 2016/008 1976 A1 Mar. 24, 2016 FORMULATIONS OF WATER-SOLUBLE tion Ser. No. 61/852,243, filed Mar. 15, 2013, entitled “FOR DERVATIVES OF VITAMIN E AND SOFT MULATIONS OF PEG-DERIVATIVES OF VITAMIN E GEL COMPOSITIONS, CONCENTRATES AND COMPOSITIONS CONTAINING SAME, to Philip AND POWDERS CONTAINING SAME Bromley, and International PCT Application No. PCT/ US2014/25006, filed Mar. 12, 2014, published as WO 2014/ RELATED APPLICATIONS 151109 on Sep. 25, 2014, entitled “FORMULATIONS OF 0001. This application is a continuation of PCT/US2015/ WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND 051097, filed Sep. 18, 2015, entitled “PRE-SPRAY EMUL COMPOSITIONS CONTAINING SAME, which also SIONS AND POWDERS CONTAINING NON-POLAR claims priority to U.S. Provisional Application Ser. No. COMPOUNDS.” to Philip Bromley, which claims the benefit 61/852,243, filed Mar. 15, 2013, entitled “FORMULATIONS of priority to U.S. Provisional Application Ser. No. 62/052, OF PEG-DERIVATIVES OF VITAMINE AND COMPOSI 433, filed Sep. 18, 2014, entitled “PRE-SPRAY EMUL TIONS CONTAINING SAME and to U.S. Provisional SIONS AND POWDERS CONTAINING NON-POLAR Application Ser. No. 61/863,732, filed Aug. 8, 2013, entitled COMPOUNDS,” to Philip J. Bromley, and to U.S. Provi FORMULATIONS OF WATER-SOLUBLE DERIVA sional Application Ser. No. 62/052,450, filed Sep. 18, 2014, TIVES OF VITAMIN E AND COMPOSITIONS CON entitled “FORMULATIONS OF WATER-SOLUBLE TAINING SAME, each to Philip Bromley. DERIVATIVES OF VITAMINE AND SOFT GEL COMPO 0006. The subject matter of each of the above-referenced SITIONS, CONCENTRATES AND POWDERS CON applications is incorporated by reference in its entirety. TAINING SAME, to Philip J. Bromley. 0002 This application also is a continuation of PCT/ FIELD OF THE INVENTION US2015/051083, filed Sep. 18, 2015, entitled “SOFT GEL 0007 Provided herein are compositions that contain COMPOSITIONS AND PRE-GEL CONCENTRATES to water-soluble vitamin E derivative mixtures (compositions), Philip J. Bromley, which also claims the benefit of priority to such as tocopheryl polyethylene glycol succinate (TPGS), U.S. Provisional Application Ser. No. 62/052,435, filed Sep. TPGS analogs, TPGS homologs and TPGS derivatives. The 18, 2014, entitled “SOFT GEL COMPOSITIONS AND water-soluble vitamin E mixtures contain mixtures of dimers PRE-GEL CONCENTRATES. to Philip J. Bromley, and to and monomers of the vitamin E derivative. Also provided are U.S. Provisional Application Ser. No. 62/052.450, filed Sep. products containing the water-soluble vitamin E derivative 18, 2014, entitled “FORMULATIONS OF WATER mixtures, including soft gel compositions, pre-gel concen SOLUBLE DERIVATIVES OF VITAMIN E AND SOFT trates, capsules and soft gels compositions that contain the GEL COMPOSITIONS, CONCENTRATES AND POW pre-gel concentrates, and powders, and methods for prepar DERS CONTAINING SAME to Philip J. Bromley. ing the products. Methods for preparing the products are 0003. This application is related to U.S. application Ser. provided. No. 14/866,717, filed the same day herewith, entitled “PRE SPRAY EMULSIONS AND POWDERS CONTAINING BACKGROUND NON-POLAR COMPOUNDS.” to Philip J. Bromley. U.S. application Ser. No. 14/866,717 also claims priority to U.S. 0008. Non-polar ingredients and compounds are not eas Provisional Application Ser. No. 62/052,433, filed Sep. 18, ily dissolved in aqueous solutions, such as water or other 2014, entitled “PRE-SPRAY EMULSIONS AND POW polar solvents. A number of non-polar ingredients and com DERS CONTAINING NON-POLAR COMPOUNDS to pounds are used in compositions for human ingestion. These Philip J. Bromley, and to U.S. Provisional Application Ser. include, for example, pharmaceuticals, nutraceuticals and/or No. 62/052,450, filed Sep. 18, 2014, entitled “FORMULA dietary Supplements. Exemplary of non-polar ingredients are TIONS OF WATER-SOLUBLE DERIVATIVES OF VITA Vitamins and minerals, fatty acids, and other non-polar com MIN E AND SOFT GEL COMPOSITIONS, CONCEN pounds, non-polar bioactive agents and non-polar ingredi TRATES AND POWDERS CONTAINING SAME to ents. Because of poor water Solubility, inclusion of non-polar Philip J. Bromley. ingredients and compounds in products for human consump 0004. This application also is related to U.S. application tion, for example, in Supplements, foods and beverages, can Ser. No. 14/866,724, filed the same day herewith, entitled be problematic, and the amount of non-polar ingredient that SOFT GEL COMPOSITIONS AND PRE-GEL CONCEN can be included is limited. TRATES.” to Philip J. Bromley. U.S. application Ser. No. 0009 Water-soluble forms of vitamin E, such as TPGS 14/866,724 also claims priority to U.S. Provisional Applica (D-O-tocopheryl polyethylene glycol Succinate), in particular tion Ser. No. 62/052,435, filed Sep. 18, 2014, entitled “SOFT TPGS 1000 (D-C-tocopheryl polyethylene glycol 1000 suc GEL COMPOSITIONS AND PRE-GEL CONCEN cinate), have been approved by the FDA as vitamin E nutri TRATES.” to Philip J. Bromley, and to U.S. Provisional tional supplements. TPGS is a stable, tasteless and odorless Application Ser. No. 62/052,450, filed Sep. 18, 2014, entitled source of readily bioavailable vitamin E that does not hydro FORMULATIONS OF WATER-SOLUBLE DERIVA lyze under normal conditions. TPGS, TPGS homologs, TPGS TIVES OF VITAMIN E AND SOFT GEL COMPOSI analogs and TPGS derivatives also are used as Surfactants, TIONS, CONCENTRATES AND POWDERS CONTAIN and have been used to prepare stabilized formulations of food, ING SAME, to Philip J. Bromley. beverage, pharmaceutical or nutraceutical products contain 0005. This application also is related to U.S. patent appli ing non-polar compounds. TPGS (and homologs, analogs and cation Ser. No. 14/207,310, filed Mar. 12, 2014, published as derivatives) has been used as a solubilizing agent for Such US-2014-0271593-A1 on Sep. 18, 2014, entitled “FORMU stabilized formulations, such as water-soluble formulations LATIONS OF WATER-SOLUBLE DERIVATIVES OF that contain water-insoluble non-polar compounds, such as VITAMIN E AND COMPOSITIONS CONTAINING drugs, vitamins, or other biologically active compounds, Such SAME.” which claims priority to U.S. Provisional Applica as natural and non-natural omega-fatty acids. Thus, TPGS US 2016/008 1976 A1 Mar. 24, 2016 possesses the dual function of providing additional dietary of the dimer form of the vitamin E derivative product. One Vitamin E and providing stabilization to a formulation. advantageous property of the higher dimer-containing water 0010 Available products containing non-polar com soluble vitamin E derivative compositions is that, when pounds, particularly products for human consumption, Such diluted into foods and beverages, the resulting products have as food and beverage products containing non-polar com greater clarity and stability than products produced by addi pounds, and methods for formulating Such products, are lim tion of the same concentrates, except that the concentrates ited. In addition, the amount, or concentration, of non-polar containa water-soluble vitamin Ederivative composition that compounds in available food and beverage products is limited contains less than 13% dimer. due to the display of undesirable organoleptic properties 0014 Generally, vitamin E derivative compositions have when the amount of non-polar compound is increased. Thus, been prepared to contain as much monomer form as possible there is a need to develop products for human consumption, and contain dimer only as an undesired byproduct in low Such as food and beverage products, that contain non-polar concentration. The water-soluble vitamin E derivative mix compounds and methods for making the products. There is an tures (compositions) provided herein can be used as the PEG additional need to develop products for human consumption, derivative of vitamin E, such as TPGS, in addition to or in Such as food and beverage products, that contain a higher place of another Surfactant, such as a polysorbate, in any amount of non-polar compound than is offered in available composition or formulation that contains a PEG derivative of food and beverage products.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Critical Exposure Consultations Consultant: (All) Consultation Type: (All)
    7/1/2020 - 6/30/2021 Critical Exposure Consultations Consultant: (all) Consultation Type: (all) Drills:No Drills FPICN - Jacksonville 6811 Exposures Call Date Expo # Consultant(s) Consult SPI Consult Type Primary Substance HCF 07/01/2020 00:18 M219087 BERNSTEIN, JEFFREY CUTINO, Letizia SPI Consultation Marijuana (Edible Preparation) JUPITER MEDICAL CENTER 0 07/01/2020 04:02 J2281051 Thundiyil, Josef A-BARNES, Beverly Provider Consultation Cannabis sativa (Botanic name) UF HEALTH NORTH 07/01/2020 11:55 T2289078 AALEGUAS, Alfred BOOS, Szilvia SPI Consultation CHLORINE DIOXIDE ST. JOSEPHS HOSPITAL NORTH 07/01/2020 13:08 T2289083 AALEGUAS, Alfred CULLEN, Tom SPI Consultation CLONIDINE ALL CHILDREN'S HOSPITAL 07/01/2020 13:44 T2289084 AALEGUAS, Alfred BOOS, Szilvia SPI Consultation Windshield Washer Fluid (General TAMPA GENERAL HOSPITAL formulation) 07/01/2020 13:45 M219092 BERNSTEIN, JEFFREY SARMIENTO, Sergio SPI Consultation Metoprolol (Metoprolol 50 MG) MOUNT SINAI MEDICAL CENTER 4 Tablet BERNSTEIN, JEFFREY CUTINO, Letizia SPI Consultation 07/01/2020 15:35 M219094 BERNSTEIN, JEFFREY LOPEZ, Eddie SPI Consultation Liquid soap ST MARY'S HOSPITAL 6 07/01/2020 17:37 T2289109 AALEGUAS, Alfred MORLEY, Rachael SPI Consultation LEAD ALL CHILDREN'S HOSPITAL AALEGUAS, Alfred NGO, Kiet[InActive] SPI Consultation ARNOLD, Justin WEBB, Charisse SPI Consultation 07/01/2020 20:41 M219099 BERNSTEIN, JEFFREY SARMIENTO, Sergio SPI Consultation Xanax (Alprazolam 0.25 MG) Oral JFK MEDICAL CENTER NORTH 0 Tablet CAMPUS 07/01/2020 22:54 M219099 BERNSTEIN, JEFFREY
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]